Gilead Sciences Inc said that its antiviral drug has shown good results. Remdesivir greatly improves the clinical recovery of COVID-19 patients, which reduces the risk of death. The company stated that these results will need to be confirmed in upcoming clinical trials.
Gilead Sciences Inc said that the data of 312 patients in their late stages were analyzed compared to 818 other patients, the analysis showed that 74.4% of late-stage patients treated with Remdesivir had recovered on the fourteenth day compared to 59.0% of patients who did not receive it.
The death rate among patients treated with Remdesivir was 7.6% on the 14th day, compared to 12.5% of the other patients.